Pd42-08 Can We Use Immunohistochemistry as Predicting Factor of Successful Treatment With Intensified Neoadjuvant Treatment in High-Risk Prostate Cancer: A Subanalysis of the Arneo Trial?

You have accessJournal of UrologyProstate Cancer: Markers II (PD42)1 May 2024PD42-08 CAN WE USE IMMUNOHISTOCHEMISTRY AS PREDICTING FACTOR OF SUCCESSFUL TREATMENT WITH INTENSIFIED NEOADJUVANT TREATMENT IN HIGH-RISK PROSTATE CANCER: A SUBANALYSIS OF THE ARNEO TRIAL? Alexander Giesen, Gaëtan Devos, Lorenzo Tosco, Marcella Baldewijns, Thomas Gevaert, Karolien Goffin, Petit Valentin, Mai Cindy, Raskin Yannic, Van Haute Carl, Lieven Goeman, De Meerleer Gert, Berghen Charlien, Devlies Wout, Claessens Frank, Van Poppel Hendrik, Everaerts Wouter, and Joniau Steven Alexander GiesenAlexander Giesen , Gaëtan DevosGaëtan Devos , Lorenzo ToscoLorenzo Tosco , Marcella BaldewijnsMarcella Baldewijns , Thomas GevaertThomas Gevaert , Karolien GoffinKarolien Goffin , Petit ValentinPetit Valentin , Mai CindyMai Cindy , Raskin YannicRaskin Yannic , Van Haute CarlVan Haute Carl , Lieven GoemanLieven Goeman , De Meerleer GertDe Meerleer Gert , Berghen CharlienBerghen Charlien , Devlies WoutDevlies Wout , Claessens FrankClaessens Frank , Van Poppel HendrikVan Poppel Hendrik , Everaerts WouterEveraerts Wouter , and Joniau StevenJoniau Steven View All Author Informationhttps://doi.org/10.1097/01.JU.0001008560.54103.65.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Patients with high-risk prostate cancer (PCa) have a high risk of biochemical recurrence and metastatic progression after local treatment. New treatment modalities are emerging. The ARNEO study is a double-blind, placebo-controlled trial on the role of neoadjuvant degarelix with or without apalutamide before radical prostatectomy (RP) in men with high-risk PCa. Diagnostic biopsies from 76 patients were available for immunohistochemical (IHC) staining of ERG, PSMA, Ki67, GR, PTEN and p53. The primary endpoint of the study was minimal residual disease (MRD) on final pathology and the key secondary endpoint was biochemical recurrence (BCR). The correlation between IHC and BCR were studied. METHODS: Prostate biopsies were IHC stained for PTEN, ERG, PSMA, Ki67, P53 and GR. All IHC were interpreted by a dedicated uropathologist and coded as negative/positive (ERG, GR), low/high (PSMA, Ki67) or loss of function mutation/wild type (PTEN, p53). RESULTS: With a median follow-up of 32 months, 26 patients (29%) developed BCR. When comparing patients with negative and positive staining, 9 (28%) versus 12 (27%) patients and 10 (28%) versus 11 (28%) patients experienced BCR for ERG (p=0.94) and GR (p=0.98), respectively. Of patients with high PSMA expression, 13 patients (30%) developed BCR. Of patients with low PSMA expression, 8 (24%) developed BCR (p=0.56). Of patients with low Ki67, 5 (11%) patients developed BCR, while 16 (52%) patients with high Ki67 experienced BCR (p<0.001) (Figure 1). Finally, when comparing patients with a loss of function mutation and wild-type in PTEN and p53, 14 (30%) versus 7 (23%) and 6 (29%) versus 15 (27%) developed BCR, respectively. CONCLUSIONS: Our results suggest that a low Ki67 IHC score on diagnostic biopsy before neoadjuvant hormonal therapy could be used to predict PSA relapse after RP. IHC stains for ERG, PSMA, GR, PTEN and p53 did not predict BCR. Download PPT Source of Funding: The ARNEO trial was sponsored by Janssen Pharmaceutical and Ferring Pharmaceuticals (product and budget funding). This had however no impact on this project and data was never in possession of these companies © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e895 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Alexander Giesen More articles by this author Gaëtan Devos More articles by this author Lorenzo Tosco More articles by this author Marcella Baldewijns More articles by this author Thomas Gevaert More articles by this author Karolien Goffin More articles by this author Petit Valentin More articles by this author Mai Cindy More articles by this author Raskin Yannic More articles by this author Van Haute Carl More articles by this author Lieven Goeman More articles by this author De Meerleer Gert More articles by this author Berghen Charlien More articles by this author Devlies Wout More articles by this author Claessens Frank More articles by this author Van Poppel Hendrik More articles by this author Everaerts Wouter More articles by this author Joniau Steven More articles by this author Expand All Advertisement PDF downloadLoading ...